Literature DB >> 29763590

A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity.

Kin-Hing William Lau1, Matilda H-C Sheng2.   

Abstract

Information about the molecular mechanisms leading to the activation of the osteoclast is relatively limited. While there is compelling evidence that the signaling mechanisms of Src and integrin β3 are essential for osteoclast activation, the regulation of these two signaling mechanisms is not fully understood. In this review, evidence supporting a novel regulatory axis of osteoclast activation that plays an upstream regulatory role in both the Src and integrin β3 signaling during osteoclast activation is discussed. This regulatory axis contains three unique components: a structurally unique transmembrane protein-tyrosine phosphatase, PTP-oc, EphA4, and miR17. In the first component, PTP-oc activates the Src signaling through dephosphorylation of the inhibitory tyr-527 of Src. This in turn activates the integrin β3 signaling, enhances the JNK2/NFκB signaling, promotes the ITAM/Syk signaling, and suppresses the ITIM/Shp1 signaling; the consequence of which is activation of the osteoclast. In the second component, EphA4 inhibits osteoclast activity by suppressing the integrin β3 signaling. PTP-oc relieves the suppressive actions of EphA4 by directly dephosphorylating EphA4. In the third component, PTP-oc expression is negatively regulated by miR17. Accordingly, suppression of miR17 during osteoclast activation upregulates the PTP-oc signaling and suppresses the EphA4 signaling, resulting in the activation of the osteoclast. This regulatory axis is unique, in that each of the three components acts to exert suppressive action on their respective immediate downstream inhibitory step. Because the final downstream event is the EphA4-mediated inhibition of osteoclast activation, the overall effect of this mechanism is the stimulation of osteoclast activity. Published by Elsevier Inc.

Entities:  

Keywords:  Bone resorption; EphA4; Integrin β(3); Osteoclasts; Protein-tyrosine phosphatase; Src; miR17∼92

Mesh:

Substances:

Year:  2018        PMID: 29763590      PMCID: PMC5985224          DOI: 10.1016/j.abb.2018.05.014

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  110 in total

1.  Upregulation of osteoclast alpha2beta1 integrin compensates for lack of alphavbeta3 vitronectin receptor in Iraqi-Jewish-type Glanzmann thrombasthenia.

Authors:  Michael A Horton; Helen M Massey; Nurit Rosenberg; Brian Nicholls; Uri Seligsohn; Adrienne M Flanagan
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

2.  Osteoclasts and integrins.

Authors:  Steven L Teitelbaum
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

Review 3.  Protein tyrosine phosphatases in osteoclasts.

Authors:  Shira Granot-Attas; Hilla Knobler; Ari Elson
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2007       Impact factor: 1.807

Review 4.  Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.

Authors:  Samson T Jacob; Tasneem Motiwala
Journal:  Cancer Gene Ther       Date:  2005-08       Impact factor: 5.987

Review 5.  Advances in the regulation of osteoclasts and osteoclast functions.

Authors:  B F Boyce
Journal:  J Dent Res       Date:  2013-08-01       Impact factor: 6.116

6.  An osteoclastic protein-tyrosine phosphatase is a potential positive regulator of the c-Src protein-tyrosine kinase activity: a mediator of osteoclast activity.

Authors:  K-H William Lau; Li-Wha Wu; Matilda H-C Sheng; Mehran Amoui; Sung Min Suhr; David J Baylink
Journal:  J Cell Biochem       Date:  2006-04-01       Impact factor: 4.429

7.  High-content analysis of proapoptotic EphA4 dependence receptor functions using small-molecule libraries.

Authors:  Claudiu M Nelersa; Henry Barreras; Erik Runko; Jerome Ricard; Yan Shi; Stephanie J Glass; John L Bixby; Vance P Lemmon; Daniel J Liebl
Journal:  J Biomol Screen       Date:  2012-04-04

8.  Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats.

Authors:  H C Blair; S E Jordan; T G Peterson; S Barnes
Journal:  J Cell Biochem       Date:  1996-06-15       Impact factor: 4.429

9.  Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim.

Authors:  Toru Akiyama; Phillippe Bouillet; Tsuyoshi Miyazaki; Yuho Kadono; Hirotaka Chikuda; Ung-Il Chung; Akira Fukuda; Atsuhiko Hikita; Hiroaki Seto; Takashi Okada; Toshiya Inaba; Archana Sanjay; Roland Baron; Hiroshi Kawaguchi; Hiromi Oda; Kozo Nakamura; Andreas Strasser; Sakae Tanaka
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

Review 10.  Osteoclastogenesis and osteoimmunology.

Authors:  Wei Feng; Wei Xia; Qing Ye; Weibing Wu
Journal:  Front Biosci (Landmark Ed)       Date:  2014-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.